Biocon Biologics

Biocon Biologics is a medical company that develops biosimilars. It offers spanning recombinant human Insulin (rh-Insulin), insulin analogs, monoclonal antibodies, and other recombinant proteins for the treatment of diabetes, cancer, autoimmune conditions, and other life-threatening diseases.

TypeSubsidiary
Parent CompanyBiocon
Founded1978
Biocon Biologics was founded in 1978
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Biocon Biologics Financials and Metrics

Summary Metrics

Founding Date

1978

Total Funding

$255.2 m

Investors

In total, Biocon Biologics had raised $255.2 m. Biocon Biologics is a subsidiary of Biocon

Biocon Biologics Online and Social Media Presence

Embed Graph

Biocon Biologics News and Updates

Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash

BENGALURU, India, Feb. 28, 2022 /PRNewswire/ -- Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), has entered into a definitive agreement with its partner Viatris Inc. (NASDAQ: VTRS). Accordingly, Biocon Biologics Ltd. (BBL) will acquire Viatris'...

Viatris to contribute its biosimilars portfolio to Biocon Biologics for up to $3.335 billion, shares jump 4% premarket

Viatris Inc. , the company formed by the merger of Mylan and Pfizer Inc. unit Upjohn in 2020, said Monday it has reached an agreement to combine its biosimilars portfolio with Biocon Biologics Ltd. for up to $3.335 billion. The company said the move is the first in a planned series of asset sales t…

Biocon Biologics To Acquire Viatris’ Biosimilars Assets For Up To $3.34 Billion

Viatris will receive a cash payment of up to $2.34 billion and CCPS in Biocon Biologics, valued at $1 billion.

Biocon Biologics Approves Merger With Serum Institute's Subsidiary

Biocon Biologics' board approved a merger with a new vaccine subsidiary of the Serum Institute.

Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection

PITTSBURGH and BENGALURU, India, Nov. 16, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) and Biocon Biologics Ltd. today announced the U.S. launch of interchangeable biosimilars SEMGLEE® (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn)...

Biocon Biologics to offer 15 pc stake to Serum Institute Life Sciences at valuation of $4.9B

Biocon Biologics will also establish, at its cost, a vaccine R&D division to support the strategic alliance in developing both vaccines and biologics for communicable diseases.
Show more

Biocon Biologics Frequently Asked Questions

  • When was Biocon Biologics founded?

    Biocon Biologics was founded in 1978.

  • How many employees does Biocon Biologics have?

    Biocon Biologics has 2,431 employees.

  • Who are Biocon Biologics competitors?

    Competitors of Biocon Biologics include Balmes Transplantation, Spiral Therapeutics and CMG Pharmaceutical.